Madrid, Spain

Carlos Martinez Alonso

USPTO Granted Patents = 6 


Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 65(Granted Patents)


Company Filing History:


Years Active: 1998-2011

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Carlos Martinez Alonso

Introduction

Carlos Martinez Alonso is a prominent inventor based in Madrid, Spain. He has made significant contributions to the field of immunology, holding a total of 6 patents. His work focuses on innovative methods for regulating immune responses, showcasing his expertise and dedication to advancing medical science.

Latest Patents

One of his latest patents involves immune regulation based on the depletion of CD69+ cells. This patent discloses methods for treating subjects with disorders characterized by unwanted immune responses. It includes the administration of effective amounts of early activation molecule agonists, antagonists, or depletors. Additionally, human monoclonal antibodies specific to these early activation molecules and their methods of use are also disclosed. Another notable patent pertains to the use of beta recombinase in eukaryotic cells, particularly for transgenic work.

Career Highlights

Throughout his career, Carlos has worked with esteemed organizations, including the Consejo Superior de Investigaciones Científicas. His research has significantly impacted the understanding of immune regulation and transgenic technologies.

Collaborations

Carlos has collaborated with notable colleagues such as Jose Mario Garcia and Jose Miguel Frade, contributing to a rich exchange of ideas and advancements in their respective fields.

Conclusion

Carlos Martinez Alonso's innovative work and patents reflect his commitment to improving medical treatments and understanding immune responses. His contributions continue to influence the scientific community and pave the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…